Indication
For the treatment of invasive candidiasis in adults. Consideration should be given to official guidance on the appropriate use of antifungal agents.
Medicine details
- Medicine name:
- rezafungin acetate (Rezzayo)
- SMC ID:
- SMC2659
- Pharmaceutical company
- Napp Pharmaceuticals Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Publication due date:
- 07 October 2024
- SMC meeting date:
- 03 September 2024
- Patient group submission deadline:
- 07 May 2024